Epi-collect: Data Collection During Video EEG Monitoring and at Patient's Home
Epilepsy is a group of neurological disorders characterized by propensity for spontaneous epileptic seizures. Epileptic seizures are the result of excessive and abnormal nerve cell activity in the brain. About 0.7-1% of the world population suffers from seizures. The most common treatment is based on seizure medications that enables about 2/3 of the patients to control their seizures. However, about 20 million patients worldwide, suffer from unpredictable seizures without remedy, and are resistant to medication.
In this study EEG and other physiologic signals are collected using wearable sensors, from Epilepsy patients who are at risk of experiencing seizures. The collected signals will be used for developing algorithms that may identify pre-seizure and seizure related periods.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Tel Aviv, Israel, 64239
- Tel Aviv Sourasky Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age >18
- Known diagnosis of Epilepsy
- Expected to experience seizures during the period of the study as determined by the PI.
- Able to meet with the Sponsor representative at home
Exclusion Criteria:
- Trauma/broken skin on forehead.
- Patient can not follow or comply with instructions
- Patients who are unable to independently provide an informed consent
- Patients with major psychiatric co-morbidities
- Patients with psychogenic non-epileptic seizures
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Successful data collection during hospitalization
Time Frame: 12 hours daily for up to 5 days
|
Continuous recording from wearable sensors of physiologic signals during hospitalization in the video EEG unit
|
12 hours daily for up to 5 days
|
|
Successful data collection during at home monitoring
Time Frame: 12 hours daily for up to 14 days
|
Continuous recording from wearable sensors of physiologic signals during at home monitoring
|
12 hours daily for up to 14 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CA-EPIPRO-TASMC-HOSP-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NCT03860298CompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant Epilepsy
-
NCT03916848Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, Focal
-
NCT06153186TerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence Epilepsy
-
NCT06310954RecruitingEpilepsy Intractable | Epilepsy in Children
-
NCT01311440CompletedEpilepsy | Generalized Epilepsy | Focal Epilepsy
-
NCT00150813CompletedEpilepsy, Tonic-clonic
-
NCT00150787CompletedEpilepsy, Tonic-clonic
-
NCT06602570Not yet recruitingEpilepsy Intractable | Epilepsy in Children
-
NCT03278210CompletedFocal Epilepsy | Epilepsy Intractable
-
NCT04569708CompletedEpilepsy | Epilepsy; Seizure | Rolandic Epilepsy | Rolandic Epilepsy, Benign | Centrotemporal Epilepsy | Centrotemporal; EEG Spikes, Epilepsy of Childhood
Clinical Trials on Neuroelectrics Enobio 8(R)
-
NCT02950506Withdrawn
-
NCT04842318Recruiting
-
NCT05713500Completed
-
NCT00129090Completed
-
NCT01898494Active, not recruitingHuman Papilloma Virus Infection | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the Oropharynx | Stage IVB Squamous Cell Carcinoma of the Oropharynx
-
NCT05874778Not yet recruitingRadiotherapy | Advanced Diffuse Large B-Cell Lymphoma | Extra-nodal Involvement, Large Mass
-
NCT01637558Completed
-
NCT06114628Recruiting
-
NCT00096161CompletedAcute Myeloid Leukemia | Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Plasma Cell Myeloma | Myelodysplastic/Myeloproliferative Neoplasm | Graft Versus Host Disease | Chronic Myelogenous Leukemia, BCR-ABL1 Positive
-
NCT05888493Active, not recruiting